endocrine and metabolism

7/28/2019 Endocrine and Metabolism

1/34


2/34


3/34


4/34


5/34


6/34

Glucose-stimulated insulin release from pancreas B cell


7/34


8/34


9/34


10/34


11/34

Diabetes Mellitus and Starvation

Similarity: Lack of intracellular energy

Difference: What causes the problem


12/34

Cause of the problem

DM: Deficient mechanism to obtain energy

from glucose

- Starvation: Lack of nutrients input for the

provision of fuel substances


13/34

Alternative to obtain energy in DM and

Starvation

a. Switch from carbohydrate to fat

metabolism

b. Switch from gluconeogenesis to ketoneproduction

Consequences (what are they?) have to be

monitored.


14/34

Diabetes Mellitus type1

- Less common than type 2

- Autoimmune destruction of pancreaticB cells

- Severe insulin deficiency

- Diabetic ketoacidosis


15/34

Diabetes Mellitus type 2

- Insulin resistance

- Do not require insulin treatment

- Managed with diet alone or

diet plus medications


16/34

Purpose of medications:

- Enhance endogenous insulin secretion

(sulfonylureas)

- Decrease insulin resistance

- Decrease intestinal carbohydrate

absorption (-glycosidase inhibitors)


17/34

Explain biochemical aspects of:

1. Hyperglycaemia

2. Glucosuria

3. Decreased glycogenesis

4. Decreased fatty acid synthesis

5. Increased lypolysis


18/34

6. Increased fatty acids in blood

7. Ketonaemia

8. Ketonuria

9. Metabolic acidosis

10. Negative Nitrogen Balance


19/34

Explanation of 1-4

Actions of insulin on target tissues


20/34

Hyperglycaemia

- Decreased glucose uptake by insulin

dependent glucose transporter(Glut 4, muscle, adipose tiss)

- Decreased glycogenesis

Not sufficient insulin to activate

phosphodiesterase, enzyme for

conversion of cAMP to AMP, meaning

to decrease cAMP concentration

cAMP inhibiting factor in glycogenesis


21/34

Explanation of 5 6

Due to a switch from utilization ofglucose to

fat for source ofenergy.

Low levels of oxaloacetate (OAA) in liver

Ketone body production increases


22/34

Explanation of 7 8

Increased production of ketone bodies

Less utilization in muscle (low OAA)

Develops ketonaemia in type 1 DM and

type 2 DM with insulinopenia.


23/34

Glucose is insulin secretagogue for insulin secretion

Type 2 DM: Deficient control of insulin secretion


24/34

Explanation 9 - 10

In severe cases of DM,

tissue protein utilized for energy

Cysteine sulphates acid urine

Negative N-balance due to ineffective amino

acid metabolism.


25/34

Complications and Therapy

Advanced glycation end products (AGEs)

A serious complication of diabetes

Glycoprotein = covalent linkage of sugar to protein

Can occur nonenzymatically


26/34

Glycation causes change to protein function

Circulation, joint and vision problems.

Nonenzymatic glycation of Hb (glycated Hb) is

Used to estimate blood glucose over past several

months


27/34

Chronic Complications

Microvascular complications induced by:

1. Polyol pathway

2. AGE formation

3. Protein kinase C (PKC)

4. Hexosamine Pathway


28/34

ad 1. Aldose reductase converts glucose to sorbitol

In hyperglycemia: accumulation of sorbitol

osmotic stress in nerves, endothelial cells,

eye lens (cataract)


29/34


30/34

ad 2. AGEs can cause :

- Microvascular damage

- Formation of glycated HbA (= HbA1c)

Used as index of glycemic control over

preceding 2-3 months


31/34

ad 3. Intracellular hyperglycemia in endothelium

increased DAG (diacylglycerol) activates

protein kinase C (PKC) effects on blood

flow and endothelial permeability.


32/34

ad 4. Increase of glucose entering hexosamine

pathway produces substrates that

can bind covalently to transcription

factors stimulate protein expression

e.g. transforming growth factor,

enhancing microvascular damage


33/34

Gluconeogenesis Inhibitors

Metformin improves sensitivity to insulin in type

2 DM

Stimulates glucose uptake by glucose

transporters in peripheral tissues

Increases binding of insulin to insulin receptors

Stimulates tyrosine kinase activity of insulin

reseptorInhibits glukoneogenesis in liver


34/34

REFERENCES1. Medical Biochemistry (MASTER MEDICINE)

Brownie, A.C., Kernohan, J.C. 2nd ed. 2005

2. BIOCHEMISTRY

Garrett, R.H., Grisham, C.M. 3rd ed. 20053. Pathophysiology of Disease

McPhee, S.J., Ganong, W.F. 5th ed. 2006

endocrine and metabolism

Documents